Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- Submitting institution
-
University College London
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 5453
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(15)01037-5
- Title of journal
- LANCET
- Article number
- -
- First page
- 1163
- Volume
- 387
- Issue
- 10024
- ISSN
- 0140-6736
- Open access status
- Out of scope for open access requirements
- Month of publication
- March
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
https://ars.els-cdn.com/content/image/1-s2.0-S0140673615010375-mmc1.pdf
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
46
- Research group(s)
-
-
- Citation count
- 906
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Corresponding author
- Non-English
- No
- English abstract
- -